Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploring the Therapeutic Potential of Xanthine Oxidase Inhibitors (Allopurinol) in Coronary Artery Disease
2005-003081-42Phase 4Completed
- Sponsor
- University of Dundee
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronary arteriosclerosis, angina pectoris and myocardial infarction (MI) comparing Allopurinol with Placebo (2 arms). Primary endpoints: Change in endothelial function (plethysmography and vasoactive infusions) and Change in endothelial function (flow-mediated dilation by ultrasound). Started Jul 2005; status: completed.
02
Drugs
allopurinol
03
Conditions
coronary arteriosclerosisangina pectorismyocardial infarction (MI)
Beyond the preview
Go deeper on 2005-003081-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003081-42.